



HYPERTENSION

Dr Rajesh T Eapen
ATLAS Hospital
Muscat




History of Hypertension



- Historical records as far back as 2600 B.C. hold mention of “hard pulse disease”
- First treatments: Leeching/phlebotomy, acupuncture
- Hippocrates recommended phlebotomy
- 120 AD – cupping of the spine to draw animal spirits down and out was recommended

History of Hypertension



Lithograph showing the leeching of a patient, date unknown.

*National Library of Medicine,
Bethesda, Maryland*



- No way to measure prior to 1700s
 - Physicians could estimate by feeling pulse

Measurement of HTN

- 1733 – Reverend Stephen Hales measured the intra-arterial BP of a horse

Measurement of HTN





Fig 1 *Stephen Hales (1677–1761) (by courtesy of the Wellcome Trustees)*


- 1905 – N.C. Korotkoff reported on the method of auscultation of brachial artery, the method which is widely used today
 - Allowed auscultation of diastolic BP as well



Blood pressure

- is the amount of force on the walls of the arteries as the blood circulates around the body.

Blood pressure is the measurement of force applied to artery walls



© Original Artist

Reproduction rights obtainable from
www.CartoonStock.com



Factors Influencing Blood Pressure

Blood Pressure

=


Cardiac Output

x

**Systemic Vascular
Resistance**

Factors Influencing BP

- HR
- SNS/PNS
- Vasoconstriction/vasodilation
- Fluid volume
 - Renin-angiotensin
 - Aldosterone
 - ADH



Hypertension

Definition

- Hypertension is sustained elevation of BP
 - Systolic blood pressure ≥ 140 mm Hg
 - Diastolic blood pressure ≥ 90 mm Hg




Classification (JNC7)	Systolic pressure	Diastolic pressure
	mmHg	mmHg
Normal	90–119	60–79
High normal or prehypertension	120–139	80–89
Stage 1 hypertension	140–159	90–99
Stage 2 hypertension	≥160	≥100
<u>Isolated systolic</u> <u>hypertension</u>	≥140	<90

Accurate BP measurement

- Who checks your patients BP?
 - You or Staff
 - IF Staff – Do they know what to listen for or do they use automated equipment
 - Seated quietly for 5 minutes
 - Appropriate size cuff
 - Inflate 20-30 mmHg above loss of radial pulse
 - Deflate at 2mmHg per second
 - 1st sound SBP ; Disappearance of Korotkoff sound (phase 5) is DBP
 - Confirm Elevated blood pressure within 2months(stage 1) – shorter for stage 2 if new onset

Hypertension

- For persons over age 50, SBP is more important than DBP as a CVD risk factor
- Starting at 115/75 mmHg, CVD risk doubles with each increment of 20/10 mmHg throughout the BP range



Classification of Hypertension

- **Primary (Essential) Hypertension**
 - **Elevated BP with unknown cause**
 - **90% to 95% of all cases**
- **Secondary Hypertension**
 - **Elevated BP with a specific cause**
 - **5% to 10% in adults**

Classification of Hypertension

- **Primary Hypertension**
 - **Contributing factors:**
 - **↑ SNS activity**
 - **Diabetes mellitus**
 - **↑ Sodium intake**
 - **Excessive alcohol intake**



Classification of Hypertension

- **Secondary Hypertension**
 - **Contributing factors:**
 - **Coarctation of aorta**
 - **Renal disease**
 - **Endocrine disorders**
 - **Neurologic disorders**
 - **Rx: Treat underlying cause**

Risk Factors for Primary Hypertension

- **Age (> 55 for men; > 65 for women)**
- **Alcohol**
- **Cigarette smoking**
- **Diabetes mellitus**
- **Elevated serum lipids**
- **Excess dietary sodium**
- **Gender**

Risk Factors for Primary Hypertension

- **Family history**
- **Obesity (BMI \geq 30)**
- **Ethnicity (African Americans)**
- **Sedentary lifestyle**
- **Socioeconomic status**
- **Stress**

Hypertension

Clinical Manifestations

- **Frequently asymptomatic until severe and target organ disease has occurred**
 - **Fatigue, reduced activity tolerance**
 - **Dizziness**
 - **Palpitations, angina**
 - **Dyspnea**

How to Prevent HTN


Lifestyle modifications prevent HTN and include:

- Maintaining a Healthy Weight
- Reduce Salt/Sodium Intake
- Increase Physical Exercise
- Smoking Cessation
- Limit Alcohol Consumption
- Limit Fat Intake
- Control Diabetes
- Stress Relieving Techniques



Hypertension: Complications

- Complications are primarily related to development of atherosclerosis (“hardening of arteries”), or fatty deposits that harden with age



Hypertension

Complications

The common complications are target organ diseases occurring in the

- Heart**
- Brain**
- Kidney**
- Eyes**

Hypertension

Complications

- **Hypertensive Heart Disease**
 - **Coronary artery disease**
 - **Left ventricular hypertrophy**
 - **Heart failure**


Hypertension

Complications

- **Cerebrovascular Disease**
 - **Stroke**
- **Peripheral Vascular Disease**
- **Nephrosclerosis**
- **Retinal Damage**




Hypertension can cause damage to the retina of the eye



A fundus view of hypertensive retinopathy in the right eye shows hemorrhages and exudates caused by hypertension.

© ISM / Prostock

Normal retina



Macula

Optic disk


Retinopathy



Hemorrhage

Aneurysms

Left Ventricular Hypertrophy



From Kissane JM: *Anderson's pathology*, ed 9, St. Louis, 1990, Mosby.

Copyright © 2004, 2000, Mosby, Inc. All Rights Reserved.

Main complications of persistent High blood pressure

Brain:

- Cerebrovascular accident (*strokes*)
- Hypertensive encephalopathy:
 - confusion*
 - headache*
 - convulsion*

Retina of eye:

- Hypertensive retinopathy

Heart:


- Myocardial infarction (*heart attack*)
- Hypertensive cardiomyopathy:
heart failure

Blood:

- Elevated sugar levels

Kidneys:

- Hypertensive nephropathy:
chronic renal failure



TO SUMMARISE

Hypertension

Diagnosis

- **Diagnosis requires several elevated readings over several weeks (unless $\geq 180/110$)**
- **BP measurement in both arms**
 - **Use arm with higher reading for subsequent measurements**

Hypertension

Diagnosis

- Ambulatory BP Monitoring
 - For “white coat” phenomenon, hypotensive or hypertensive episodes, apparent drug resistance

Treatment Goals

- **Goal is to reduce overall cardiovascular risk factors and control BP by the least intrusive means possible**
 - **BP < 140/90**
 - **In patients with diabetes or renal disease, goal is < 130/80**

Benefits of Lowering BP

	Average Percent Reduction
Stroke incidence	35–40%
Myocardial infarction	20–25%
Heart failure	50%

Table 3. Lifestyle Modifications to Manage Hypertension*

Modification	Recommendation	Approximate Systolic BP Reduction, Range
Weight reduction	Maintain normal body weight (BMI, 18.5-24.9)	5-20 mm Hg/10-kg weight loss ^{23,24}
Adopt DASH eating plan	Consume a diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat	8-14 mm Hg ^{25,26}
Dietary sodium reduction	Reduce dietary sodium intake to no more than 100 mEq/L (2.4 g sodium or 6 g sodium chloride)	2-8 mm Hg ²⁵⁻²⁷
Physical activity	Engage in regular aerobic physical activity such as brisk walking (at least 30 minutes per day, most days of the week)	4-9 mm Hg ^{28,29}
Moderation of alcohol consumption	Limit consumption to no more than 2 drinks per day (1 oz or 30 mL ethanol [eg, 24 oz beer, 10 oz wine, or 3 oz 80-proof whiskey]) in most men and no more than 1 drink per day in women and lighter-weight persons	2-4 mm Hg ³⁰

Abbreviations: BMI, body mass index calculated as weight in kilograms divided by the square of height in meters; BP, blood pressure; DASH, Dietary Approaches to Stop Hypertension.


*For overall cardiovascular risk reduction, stop smoking. The effects of implementing these modifications are dose and time dependent and could be higher for some individuals.



**There's no such thing as
a sudden heart attack.
It requires years of preparation.**



Algorithm for Treatment of Hypertension



Hypertension

Collaborative Care

- **Lifestyle Modifications**
 - **Weight reduction**
 - **Dietary changes (DASH diet)**
 - **Limitation of alcohol intake (≤ 2 drinks/day for men; ≤ 1 /day for women)**
 - **Regular physical activity**
 - **Avoidance of tobacco use**
 - **Stress management**

Hypertension

Collaborative Care

- **Nutritional Therapy: DASH Diet = Dietary Approaches to Stop HTN**
 - **Sodium restriction**
 - **Rich in vegetables, fruit, and nonfat dairy products**
 - **Calorie restriction if overweight**



Follow the DASH diet to potentially lower your blood pressure.



© ADAM, Inc.

DASH diet


(Dietary Approaches to Stop Hypertension)

FOOD GROUP	NO. SERVINGS PER DAY
Grains	7 – 8
Vegetables	4 – 5
Fruits	4 – 5
Low fat dairy foods	2 – 3
Meat, fish, poultry	2 or less
Nut, seeds, dry beans	4 – 5 weekly

Hypertension

Collaborative Care

- **Drug Therapy**
 - **Reduce SVR**
 - **Decrease volume of circulating blood**



Hypertension

Collaborative Care

- **Drug Therapy**
 - **Diuretics**
 - **Adrenergic inhibitors**
 - **β - Adrenergic blockers**
 - **ACE Inhibitors**
 - **Calcium channel blockers**





TABLE I. Drug Selection in Hypertensive Patients With or Without Other Major Conditions

Patient Type	First Drug	Add Second Drug If Needed to Achieve a BP <140/90 mm Hg	If Third Drug is Needed to Achieve a BP of <140/90 mm Hg
A. When hypertension is the only or main condition			
Black patients (African ancestry): All ages	CCB ^a or thiazide diuretic	ARB ^b or ACE inhibitor (If unavailable can add alternative first drug choice)	Combination of CCB + ACE inhibitor or ARB + thiazide diuretic
White and other non-black Patients: Younger than 60	ARB ^b or ACE inhibitor	CCB ^a or thiazide diuretic	Combination of CCB + ACE inhibitor or ARB + thiazide diuretic
White and other non-black patients: 60 y and older	CCB ^a or thiazide diuretic (Although ACE inhibitors or ARBs are also usually effective)	ARB ^b or ACE inhibitor (or CCB or thiazide if ACE inhibitor or ARB used first)	Combination of CCB + ACE inhibitor or ARB + thiazide diuretic

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate.



B. When hypertension is associated with other conditions

Hypertension <i>and</i> diabetes	ARB or ACE inhibitor Note: in black patients, it is acceptable to start with a CCB or thiazide	CCB or thiazide diuretic Note: in black patients, if starting with a CCB or thiazide, add an ARB or ACE inhibitor	The alternative second drug (thiazide or CCB)
Hypertension <i>and</i> chronic kidney disease	ARB or ACE inhibitor Note: in black patients, good evidence for renal protective effects of ACE inhibitors	CCB or thiazide diuretic ^c	The alternative second drug (thiazide or CCB)
Hypertension <i>and</i> clinical coronary artery disease ^d	β -Blocker plus ARB or ACE inhibitor	CCB or thiazide diuretic	The alternative second step drug (thiazide or CCB)
Hypertension <i>and</i> stroke history ^e	ACE inhibitor or ARB	Thiazide diuretic or CCB	The alternative second drug (CCB or thiazide)
Hypertension and heart failure	Patients with symptomatic heart failure should usually receive an ARB or ACE inhibitor + β -blocker + diuretic + spironolactone regardless of blood pressure. A dihydropyridine CCB can be added if needed for BP control.		

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate.

Hypertension: Drug Therapy

- Thiazide-type Diuretics
 - Inhibit NaCl reabsorption
 - Side effects:
 - Electrolyte imbalances: ↓ Na, ↓ Cl, ↓ K** (advise K rich foods)
 - Fluid volume depletion (monitor for orthostatic hypotension)
 - Impotence, decreased libido

Hypertension: Drug Therapy

- Adrenergic Inhibitors
 - Reduce sympathetic effects that cause HTN by:
 - Reducing sympathetic outflow
 - Blocking effects of sympathetic activity on vessels
 - Side effects
 - Hypotension
 - Varied, depending on specific drug

Hypertension: Drug Therapy

- β – adrenergic blockers (suffix “olol”)
 - (metoprolol, propranolol)
 - Block β – adrenergic receptors
 - \downarrow HR, \downarrow inotropy, reduces sympathetic vasoconstriction)
 - Side effects
 - Bradycardia, hypotension, heart failure, impotence


Hypertension: Drug Therapy

- ACE Inhibitors (suffix “pril”)
 - Enalapril, captopril
 - Prevents conversion of angiotensin I to angiotensin II, thereby preventing the vasoconstriction associated with A II.
 - Side effects
 - Hypotension, cough

Hypertension: Drug Therapy

- Calcium Channel Blockers
 - Block movement of calcium into cells, causing vasodilation
 - Side effects
 - Bradycardia, heart block





ASH/ISH HTN Guidelines 2014

Table 6. Guideline Comparisons of Goal BP and Initial Drug Therapy for Adults With Hypertension

Guideline	Population	Goal BP, mm Hg	Initial Drug Treatment Options
2014 Hypertension guideline	General ≥60 y	<150/90	Nonblack: thiazide-type diuretic, ACEI, ARB, or CCB
	General <60 y	<140/90	Black: thiazide-type diuretic or CCB
	Diabetes	<140/90	Thiazide-type diuretic, ACEI, ARB, or CCB
	CKD	<140/90	ACEI or ARB
ESH/ESC 2013 ³⁷	General nonelderly	<140/90	β-Blocker, diuretic, CCB, ACEI, or ARB
	General elderly <80 y	<150/90	
	General ≥80 y	<150/90	
	Diabetes	<140/85	ACEI or ARB
	CKD no proteinuria	<140/90	ACEI or ARB
	CKD + proteinuria	<130/90	
CHEP 2013 ³⁸	General <80 y	<140/90	Thiazide, β-blocker (age <60y), ACEI (nonblack), or ARB
	General ≥80 y	<150/90	
	Diabetes	<130/80	ACEI or ARB with additional CVD risk ACEI, ARB, thiazide, or DHPCCB without additional CVD risk
	CKD	<140/90	ACEI or ARB
ADA 2013 ³⁹	Diabetes	<140/80	ACEI or ARB
KDIGO 2012 ⁴⁰	CKD no proteinuria	≤140/90	ACEI or ARB
	CKD + proteinuria	≤130/80	
NICE 2011 ⁴¹	General <80 y	<140/90	<55 y: ACEI or ARB
	General ≥80 y	<150/90	≥55 y or black: CCB
ISHIB 2010 ⁴²	Black, lower risk	<135/85	Diuretic or CCB
	Target organ damage or CVD risk	<130/80	

Hypertension

Collaborative Care

- **Drug Therapy and Patient Teaching**
 - **Identify, report, and minimize side effects**
 - **Orthostatic hypotension**
 - **Sexual dysfunction**
 - **Dry mouth**
 - **Frequent urination**

Hypertension: The Silent Killer



Primary Hypertension

Nursing Management

Nursing Diagnoses

- **Ineffective health maintenance**
- **Anxiety**
- **Sexual dysfunction**
- **Ineffective therapeutic regimen management r/t**
 - **lack of S/S of HTN, side effects of Rx, cost of Rx, etc.**

Primary Hypertension

Nursing Management

Nursing Implementation

Health Promotion

- **Individual patient evaluation**
- **Screening programs**
- **Cardiovascular risk factor modification**

Hypertensive Crisis

- **Severe, abrupt elevation in BP**
- **The rate of ↑ in BP is more important than the absolute value**
- **Most common in patients with a history of HTN who have failed to comply with medications or who have been under-medicated**

Hypertensive Crisis

Clinical Manifestations

- Hypertensive encephalopathy (H/A, N & V, seizures, confusion, coma)
- Renal insufficiency
- Heart failure
- Pulmonary edema



Hypertensive Crisis

Nursing and Collaborative Management

Hospitalization


- IV drug therapy**
- Monitor cardiac and renal function**
- Neurologic checks**
- Determine cause**
- Education to avoid future crises**

Parenteral drugs for treatment of hypertensive emergencies*

Drug	Dose	Onset of action	Duration of action	Adverse effects*	Special indications
Vasodilators					
Sodium nitroprusside	0.25-10 µg/kg/min as IV infusion ^Δ	Immediate	1-2 min	Nausea, vomiting, muscle twitching, sweating, thiocyanate and cyanide intoxication	Most hypertensive emergencies; caution with high intracranial pressure or azotemia
Nicardipine hydrochloride	5-15 mg/h IV	5-10 min	15-30 min, may exceed 4 h	Tachycardia, headache, flushing, local phlebitis	Most hypertensive emergencies except acute heart failure; caution with coronary ischemia
Clevidipine	1-2 mg/h IV with rapid titration to max of 16 mg/h	1-2 min	5-15 min	Atrial fibrillation, nausea	All hypertensive emergencies
Fenoldopam mesylate	0.1-0.3 µg/kg per min IV infusion	<5 min	30 min	Tachycardia, headache, nausea, flushing	Most hypertensive emergencies; caution with glaucoma
Nitroglycerin	5-100 µg/min as IV infusion	2-5 min	5-10 min	Headache, vomiting, methemoglobinemia, tolerance with prolonged use	Coronary ischemia
Enalaprilat	1.25-5 mg every 6 h IV	15-30 min	6-12 h	Precipitous fall in pressure in high-renin states; variable response	Acute left ventricular failure; avoid in acute myocardial infarction
Hydralazine hydrochloride	10-20 mg IV	10-20 min IV	1-4 h IV	Tachycardia, flushing, headache, vomiting, aggravation of angina	Eclampsia
	10-40 mg IM	20-30 min IM	4-6 h IM		

Parenteral drugs for treatment of hypertensive emergencies, continued*

Drug	Dose	Onset of action	Duration of action	Adverse effects ^o	Special indications
Andrenergic inhibitors					
Labetalol hydrochloride	20-80 mg IV bolus every 10 min	5-10 min	3-6 h	Vomiting, scalp tingling, bronchoconstriction, dizziness, nausea, heart block, orthostatic hypotension	Most hypertensive emergencies except acute heart failure
	0.5-2.0 mg/min IV infusion				
Esmolol hydrochloride ^Δ	250-500 μg/kg/min by infusion; may repeat bolus after 5 min or increase infusion to 300 μg/min	1-2 min	10-30 min	Hypotension, nausea, asthma, first-degree heart block, HF	Aortic dissection, perioperative
Phentolamine	5-15 mg IV bolus	1-2 min	10-30 min	Tachycardia, flushing, headache	Catecholamine excess



This is not the end...

Projects In Knowledge

Earn Free CME Credit with the latest news in Multiple Myeloma presented at the 55th Annual American Society of Hematology (ASH) Conference

The New **PHYSICIANS TRAVEL & MEETING GUIDE**

Your #1 Resource for all medical meetings and events.

LOG ON: USERNAME: ***** PASSWORD: ***** LOGIN

Become a Member Password Help

A call to retract the JNC-8 hypertension guideline

DAVID K. CUNDIFF, MD | CONDITIONS | JANUARY 4, 2014

JAMA published the long-awaited Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-8 (JNC-8) guidelines Decem 2013. They recommended blood pressure lowering drug treatment for patients 60-years-old with systolic blood pressure (SBP) \geq 150 or diastolic blood pressure (DBP) \geq 90 mm Hg. For patients < 60-years-old, they recommended medication DBP \geq 90 mm Hg. They classified both of these recommendations as "Grade A" (strong). To say the least, the evidence-basis for the drug treatment recommendation for mild hypertension in this report is in dispute.

The JNC-8 authors simply ignored a systematic review that I co-authored in the [Cochrane Database of Systematic Reviews](#) that found no evidence supporting treatment for patients of any age with mild hypertension (SBP: 140-159 and/or 90-99) and no previous cardiovascular disease, diabetes, or renal disease (i.e. risk).

The JNC-8 hypertension guidelines are not endorsed by the National Heart Lung Blood Institute (NHLBI), the American Heart Association, the American College of Cardiology, nor any other authoritative body. They are endorsed only by the 17 panelists and various individuals such as Dr. Howard Bauchner, editor-in-chief and two colleagues from the journal's editorial staff who authored an [editorial](#) accompanying the new BP guidelines. The editorial mentioned that the guideline "appropriately acknowledged the areas of controversy." However, there was no in the guidelines about controversy concerning the BP threshold of initiating drug treatment in low risk people.

Family Practice News digital network

News and Views that Matter to Family Physicians

Home News Specialty Focus Views MD-IQ Quizzes Careers Product Zone Resources CME About Us

SEARCH: Enter keywords

Family Practice News

Receive our free **The Family Practice News** e-newsletter featuring breaking news, views and information for family physicians. Sign up today.

'JNC 8' guideline follows convoluted endgame

By: MITCHEL L. ZOLER, Family Practice News Digital Network

01/04/14 8+1 0

SHARE

PRINT/FRIENDLY

The federally funded program to produce a set of U.S. guidelines for hypertension management, a process more than 5 years in the making, came to an unusual end on December 18 when the members of what had already become the officially-disbanded JNC 8 panel published their conclusions and guideline.

No longer recognized or supported by the National Heart Lung and Blood Institute (NHLBI), the Federal agency that had organized the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) panel in 2008, and unwilling to work with potential collaborating groups like the American Heart Association (AHA), the American College of Cardiology (ACC), or the American Society of Hypertension (ASH), the 17-person group that wound up identifying themselves as the "panel members appointed to the Eighth Joint National Committee (JNC 8)."

Call them JNC Ain't.



Dr. Paul A. James

The U.S. hypertension guidelines began veering off on an unexpected course last June, when Dr. Gary H. Gibbons, NHLBI director, announced that the agency was withdrawing from issuing guidelines itself and would instead collaborate with "partner organizations."

In August, Dr. Gibbons, said that the AHA and ACC had reached an agreement with the agency to "spearhead" development of three sets of practice guidelines, for hypertension, cholesterol, and obesity. This agreement led to the release in November of the cholesterol and obesity guidelines under the auspices of the AHA and ACC, [www.escardiologynews.com/index.php](#) but instead of also releasing hypertension guidelines, the AHA and ACC as well as the NHLBI said that the process had fallen through and failed to produce guidelines.

According to Dr. Paul A. James, co-chair of the former JNC 8 panel

REGISTER NOW

SKIN DISEASE EDUCATION FOUNDATIONS

38th Annual

Kuwait Dermatology Seminar

Home News Education Conferences Opinion Resources

1 16996 16 0 0 email print

medpageTODAY Putting Breaking Medical News Into Practice

Search MedPage Today

Get customized medical news and FREE CME! **Select Your Specialty** Log In FREE CME/CCE CREDITS MY ALERTS

Each acute heart failure (AHF) episode costs the nation roughly \$26,000.

FACT or FICTION

Register Today

Earn Free CME Credits by reading the latest medical news in your specialty. Sign Up

Cardiovascular

JNC 8 Dissenters Don't Want to Ease BP Thresholds

Published: Jan 13, 2014

Download Complimentary Source PDF

By Todd Neale, Senior Staff Writer, MedPage Today

This article was produced as part of a news collaboration between: American Heart Association, American College of Cardiology, medpageTODAY

STUDY AUTHOR

Jackson Wright, MD, PhD
Director of Clinical Hypertension
University Hospitals Case Medical Center

For best viewing, click the bottom right corner for full screen.

AHA 2013 VIDEO ON THE

CardioSourceNews medpageTODAY

RESPOND TO A GLOBAL THREAT.

DEREK P. M. S. SENIOR SCIENTIST MOLECULAR STRUCTURE AND CHARACTERIZATION

Video Library

FROM INDUSTRY Provided by

Video: That's Quite a Thrill. Critical Care. SonoSite. Watch Now

CME Spotlights

AF Educational Opportunities: Managing Anticoagulation in Your Patients with Atrial Fibrillation more

MOST READ STORIES

Controversy



Thank you

